Avacta Group PLC Avacta to Present at Major European Conference
November 12 2018 - 2:00AM
RNS Non-Regulatory
TIDMAVCT
Avacta Group PLC
12 November 2018
12 November 2018
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Avacta's Chief Scientific Officer to Present Recent Data at
Major European Conference
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and reagents, is pleased to announce that its Chief
Scientific Officer, Dr Amrik Basran, will be presenting at the
Protein Engineering Society of Europe meeting, which is taking
place in Lisbon on 14 November 2018. Dr Basran will be presenting
recent data relating to the pre-clinical development of the Group's
lead therapeutic programme, a PD-L1/LAG-3 single molecule
bispecific.
Dr Basran will focus particularly on the development of novel
Affimer(R) bispecific formats that inhibit two immune checkpoints
simultaneously. PD-L1 plays a key role in suppressing the immune
system, and by blocking this checkpoint protein on tumour cells, it
assists the immune system's attack on the cancer. The blocking of
LAG-3 on T-cells helps to maintain the immune system attack and
reduce T-cell exhaustion.
The Group is developing this single molecule bispecific therapy
with a view to entering phase I clinical development in 2020, which
will yield first-in-man clinical data for the Affimer(R) platform.
Avacta is also building a pipeline of novel immuno-oncology
Affimer(R) assets for clinical development and licensing.
- Ends -
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 844 414 0452
Alastair Smith, Chief Executive Officer www.avacta.com
Tony Gardiner, Chief Financial Officer
finnCap Ltd Tel: +44 (0) 207 220 0500
Geoff Nash / Giles Rolls - Nominated www.finncap.com
Adviser
Tim Redfern - Corporate Broking
Tel: +44 (0) 203 705 9318
WG Partners Tel: +44 (0) 203 705 9317
Nigel Birks / Nigel Barnes www.wgpartners.co.uk
David Wilson / Claes Spang
Zyme Communications (Trade and Regional Tel: +44 (0)7787 502 947
Media) katie.odgaard@zymecommunications.com
Katie Odgaard
Yellow Jersey (Financial Media and Tel: +44 (0)7764 947137
IR) Tel: +44 (0)7946 424 651
Sarah Hollins avacta@yellowjerseypr.com
Katie Bairsto
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite
their shortcomings. Affimer(R) technology has been designed to
address many of these negative performance issues, principally; the
time taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer(R) technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on immuno-oncology as well as partnered development
programmes. Avacta is commercialising non-therapeutic Affimer(R)
reagents through licensing to developers of life sciences research
tools and diagnostics.
To register for news alerts by email go to
www.avacta.com/investor-news-email-alerts
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFSWFMUFASEIF
(END) Dow Jones Newswires
November 12, 2018 02:00 ET (07:00 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024